Beta 3-adrenoreceptor regulation of nitric oxide in the cardiovascular system

Journal of Molecular and Cellular Cardiology

Volumn 48, Issue 6, 2010, Pages 1088-1095

  Moens, An L ^a,b   Yang, Ronghua ^a   Watts, Vabren L ^a   Barouch, Lili A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Beta 3 adrenergic receptor; Cardiovascular; Heart failure; Nitric oxide synthase

Indexed keywords

1 (2 ETHYLPHENOXY) 3 (1,2,3,4 TETRAHYDRO 1 NAPHTHYLAMINO) 2 PROPANOL OXALATE; 4 (3 TERT BUTYLAMINO 2 HYDROXYPROPOXY) 2 BENZIMIDAZOLONE; 4 [2 [(2 HYDROXY 3 PHENOXYPROPYL)AMINO]ETHOXY] N (2 METHOXYETHYL)PHENOXYACETAMIDE; 4 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL]PHENOXYACETIC ACID; 5 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL] 1,3 BENZODIOXOLE 2,2 DICARBOXYLIC ACID; [[7 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO] 5,6,7,8 TETRAHYDRO 2 NAPHTHYL]OXY]ACETIC ACID ETHYL ESTER; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; BUCINDOLOL; CATECHOLAMINE; DOBUTAMINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INDUCIBLE NITRIC OXIDE SYNTHASE; ISOENZYME; L 748328; L 748337; L 755507; L 796568; N(G) METHYLARGININE; N(G) NITROARGININE METHYL ESTER; NEBIVOLOL; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; OXIPURINOL; PHENYLETHANOLAMINE DERIVATIVE; PINDOLOL; PLACEBO; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADRENERGIC STIMULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; CLINICAL TRIAL; CONCENTRATION RESPONSE; DIABETES MELLITUS; DIARRHEA; DRUG MECHANISM; DRUG RECEPTOR BINDING; GASTROINTESTINAL SYMPTOM; HEART FAILURE; HEART FUNCTION; HUMAN; INOTROPISM; NONHUMAN; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; TACHYCARDIA; TREMOR; VASCULARIZATION;

ANIMALS; CARDIOVASCULAR DISEASES; GENE EXPRESSION REGULATION; HEART; HEART FAILURE; HUMANS; MICE; MODELS, BIOLOGICAL; MYOCARDIUM; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE III; OXIDATIVE STRESS; RECEPTORS, ADRENERGIC, BETA-3; SIGNAL TRANSDUCTION;

EID: 77952670967     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2010.02.011     Document Type: Review

References (114)

1. Kaumann A.J., Engelhardt S., Hein L., Molenaar P., Lohse M. Abolition of (-)-CGP 12177-evoked cardiostimulation in double beta1/beta2-adrenoceptor knockout mice. Obligatory role of beta1-adrenoceptors for putative beta4-adrenoceptor pharmacology. Naunyn Schmiedebergs Arch Pharmacol 2001, 363:87-93.
2. Rouget C., Bardou M., Breuiller-Fouche M., Loustalot C., Qi H., Naline E., et al. Beta3-adrenoceptor is the predominant beta-adrenoceptor subtype in human myometrium and its expression is up-regulated in pregnancy. J Clin Endocrinol Metab 2005, 90:1644-1650.
3. Gauthier C., Langin D., Balligand J.L. Beta3-adrenoceptors in the cardiovascular system. Trends Pharmacol Sci 2000, 21(11):426-431.
4. Gauthier C., Tavernier G., Charpentier F., Langin D., Le Marec H. Functional beta3-adrenoceptor in the human heart. J Clin Invest 1996, 98:556-562.
5. Moniotte S., Kobzik L., Feron O., Trochu J.N., Gauthier C., Balligand J.L. Upregulation of beta(3)-adrenoceptors and altered contractile response to inotropic amines in human failing myocardium. Circulation 2001, 103:1649-1655.
6. Daaka Y., Luttrell L.M., Lefkowitz R.J. Switching of the coupling of the beta2-adrenergic receptor to different G proteins by protein kinase A. Nature 1997, 390:88-91.
7. Liggett S.B., Freedman N.J., DA S., Lefkowitz R.J. Structural basis for receptor subtype-specific regulation revealed by a chimeric beta 3/beta 2-adrenergic receptor. Proc Natl Acad Sci USA 1993, 90:3665-3669.
8. Soeder K.J., Snedden S.K., Cao W., Della Rocca G.J., Daniel K.W., Luttrell L.M., et al. The beta3-adrenergic receptor activates mitogen-activated protein kinase in adipocytes through a Gi-dependent mechanism. J Biol Chem 1999, 274:12017-12022.
9. Emorine L.J., Marullo S., Briend-Sutren M.M., Patey G., Tate K., Delavier-Klutchko C., et al. Molecular characterization of the human beta 3-adrenergic receptor. Science 1989, 245:1118-1121.
10. Nahmias C., Blin N., Elalouf J.M., Mattei M.G., Strosberg A.D., Emorine L.J. Molecular characterization of the mouse beta 3-adrenergic receptor: relationship with the atypical receptor of adipocytes. EMBO J 1991, 10:3721-3727.
11. Nantel F., Bonin H., Emorine L.J., Zilberfarb V., Strosberg A.D., Bouvier M., et al. The human beta 3-adrenergic receptor is resistant to short term agonist-promoted desensitization. Mol Pharmacol 1993, 43:548-555.
12. Zhao Q., Wu T.G., Jiang Z.F., Chen G.W., Lin Y., Wang L.X. Effect of beta-blockers on beta3-adrenoceptor expression in chronic heart failure. Cardiovasc Drugs Ther 2007, 21:85-90.
13. Hutchinson D.S., Bengtsson T., Evans B.A., Summers R.J. Mouse beta 3a- and beta 3b-adrenoceptors expressed in Chinese hamster ovary cells display identical pharmacology but utilize distinct signalling pathways. Br J Pharmacol 2002, 135:1903-1914.
14. Sato M., Hutchinson D.S., Evans B.A., Summers R.J. Functional domains of the mouse beta(3)-adrenoceptor associated with differential G-protein coupling. Biochem Soc Trans 2007, 35:5.
15. Boivin B., Lavoie C., Vaniotis G., Baragli A., Villeneuve L.R., Ethier N., et al. Functional β-adrenergic receptor signalling on nuclear membranes in adult rat and mouse ventricular cardiomyocytes. Cardiovasc Res 2006, 71(1):69-78.
16. Damy T., Ratajczak P., Shah A.M., Camors E., Marty I., Hasenfuss G., et al. Increased neuronal nitric oxide synthase-derived NO production in the failing human heart. Lancet 2004, 363:1365-1367.
17. Haywood G.A., Tsao P.S., von der Leyen H.E., Mann M.J., Keeling P.J., Trindade P.T., et al. Expression of inducible nitric oxide synthase in human heart failure. Circulation 1996, 93:1087-1094.
18. Massion P.B., Feron O., Dessy C., Balligand J.L. Nitric oxide and cardiac function: ten years after, and continuing. Circ Res 2003, 93:388-398.
19. Otani H. The role of nitric oxide in myocardial repair and remodeling. Antioxid Redox Signal 2009, 11(8):1913-1928.
20. Damy T., Ratajczak P., Robidel E., Bendall J.K., Oliviéro P., Boczkowski J., et al. Up-regulation of cardiac nitric oxide synthase 1-derived nitric oxide after myocardial infarction in senescent rats. FASEB J 2003, 17(13):1934-1936.
21. Drexler H., Kästner S., Strobel A., Studer R., Brodde O.E., Hasenfuss G. Expression, activity and functional significance of inducible nitric oxide synthase in the failing human heart. J Am Coll Cardiol 1998, 32(4):955-963.
22. Barouch L.A., Harrison R.W., Skaf M.W., Rosas G.O., Cappola T.P., Kobeissi Z.A., et al. Nitric oxide regulates the heart by spatial confinement of nitric oxide synthase isoforms. Nature 2002, 416:337-339.
23. Gauthier C., Leblais V., Kobzik L., Trochu J.N., Khandoudi N., Bril A., et al. The negative inotropic effect of beta3-adrenoceptor stimulation is mediated by activation of a nitric oxide synthase pathway in human ventricle. J Clin Invest 1998, 102:1377-1384.
24. Amour J., Loyer X., Le Guen M., Mabrouk N., David J.S., Camors E., et al. Altered contractile response due to increased beta3-adrenoceptor stimulation in diabetic cardiomyopathy: the role of nitric oxide synthase 1-derived nitric oxide. Anesthesiology 2007, 107:452-460.
25. Maffei A., Di Pardo A., Carangi R., Carullo P., Poulet R., Gentile M.T., et al. Nebivolol induces nitric oxide release in the heart through inducible nitric oxide synthase activation. Hypertension 2007, 50:652-656.
26. Strosberg A.D. Structure and function of the beta 3 adrenoreceptor. Adv Pharmacol 1998, 42:511-513.
27. Muzzin P., Seydoux J., Giacobino J.P., Venter J.C., Fraser C. Discrepancies between the affinities of binding and action of the novel beta-adrenergic agonist BRL 37344 in rat brown adipose tissue. Biochem Biophys Res Commun 1988, 156:375-382.
28. Bianchetti A., Manara L. In vitro inhibition of intestinal motility by phenylethanolaminotetralines: evidence of atypical beta-adrenoceptors in rat colon. Br J Pharmacol 1990, 100:831-839.
29. Dolan J.A., Muenkel H.A., Burns M.G., Pellegrino S.M., Fraser C.M., Pietri F., et al. Beta-3 adrenoceptor selectivity of the dioxolane dicarboxylate phenethanolamines. J Pharmacol Exp Ther 1994, 269:1000-1006.
30. Blin N., Nahmias C., Drumare M.F., Strosberg A.D. Mediation of most atypical effects by species homologues of the beta 3-adrenoceptor. Br J Pharmacol 1994, 112:911-919.
31. Hoffmann C., Leitz M.R., Oberdorf-Maass S., Lohse M.J., Klotz K.N. Comparative pharmacology of human beta-adrenergic receptor subtypes-characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol 2004, 369:151-159.
32. Liggett S.B. Functional properties of the rat and human beta 3-adrenergic receptors: differential agonist activation of recombinant receptors in Chinese hamster ovary cells. Mol Pharmacol 1992, 42:634-637.
33. Pietri-Rouxel F., Lenzen G., Kapoor A., Drumare M.F., Archimbault P., Strosberg A.D., et al. Molecular cloning and pharmacological characterization of the bovine beta 3-adrenergic receptor. Eur J Biochem 1995, 230:350-358.
34. Kubota Y., Nakahara T., Yunoki M., Mitani A., Maruko T., Sakamoto K., et al. Inhibitory mechanism of BRL37344 on muscarinic receptor-mediated contractions of the rat urinary bladder smooth muscle. Naunyn Schmiedebergs Arch Pharmacol 2002, 366:198-203.
35. Pott C., Brixius K., Bundkirchen A., Bolck B., Bloch W., Steinritz D., et al. The preferential beta3-adrenoceptor agonist BRL 37344 increases force via beta1-/beta2-adrenoceptors and induces endothelial nitric oxide synthase via beta3-adrenoceptors in human atrial myocardium. Br J Pharmacol 2003, 138:521-529.
36. Baker J.G. The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors. Br J Pharmacol 2005, 144:317-322.
37. Hutchinson D.S., Chernogubova E., Sato M., Summers R.J., Bengtsson T. Agonist effects of zinterol at the mouse and human beta(3)-adrenoceptor. Naunyn Schmiedebergs Arch Pharmacol 2006, 373:158-168.
38. Fisher M.H., Amend A.M., Bach T.J., Barker J.M., Brady E.J., Candelore M.R., et al. A selective human beta3 adrenergic receptor agonist increases metabolic rate in rhesus monkeys. J. Clin. Invest 1998, 101:2387-2393.
39. Kohout T.A., Takaoka H., McDonald P.H., Perry S.J., Mao L., Lefkowitz R.J., et al. Augmentation of cardiac contractility mediated by the human beta(3)-adrenergic receptor overexpressed in the hearts of transgenic mice. Circulation 2001, 104:2485-2491.
40. Lenzen G., Pietri-Rouxel F., Drumare M.F., Amiard A., Guillot S., Archimbault P., et al. Genomic cloning and species-specific properties of the recombinant canine beta3-adrenoceptor. Eur J Pharmacol 1998, 363:217-227.
41. Arch J.R. beta(3)-Adrenoceptor agonists: potential, pitfalls and progress. Eur J Pharmacol 2002, 440:99-107.
42. Arch J.R., Ainsworth A.T. Thermogenic and antiobesity activity of a novel beta-adrenoceptor agonist (BRL 26830A) in mice and rats. Am J Clin Nutr 1983, 38:549-558.
43. Larsen T.M., Toubro S., van Baak M.A., Gottesdiener K.M., Larson P., Saris W.H., et al. Effect of a 28-d treatment with L-796568, a novel beta(3)-adrenergic receptor agonist, on energy expenditure and body composition in obese men. Am J Clin Nutr 2002, 76:780-788.
44. van Baak M.A., Hul G.B., Toubro S., Astrup A., Gottesdiener K.M., DeSmet M., et al. Acute effect of L-796568, a novel beta 3-adrenergic receptor agonist, on energy expenditure in obese men. Clin Pharmacol Ther 2002, 71:272-279.
45. Guimaraes S., Moura D. Vascular adrenoceptors: an update. Pharmacol Rev 2001, 53:319-356.
46. Michel M.C., Vrydag W. Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol 2006, 147(Suppl 2):S88-S119.
47. Consoli D., Leggio G.M., Mazzola C., Micale V., Drago F. Behavioral effects of the beta3 adrenoceptor agonist SR58611A: is it the putative prototype of a new class of antidepressant/anxiolytic drugs?. Eur J Pharmacol 2007, 573:139-147.
48. Stemmelin J., Cohen C., Terranova J.P., Lopez-Grancha M., Pichat P., Bergis O., et al. Stimulation of the beta3-Adrenoceptor as a novel treatment strategy for anxiety and depressive disorders. Neuropsychopharmacology 2008, 33:574-587.
49. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001, 344:1659-1667. Investigators B-BEoST.
50. Gan R.T., Li W.M., Xiu C.H., Shen J.X., Wang X., Wu S., et al. Chronic blocking of beta 3-adrenoceptor ameliorates cardiac function in rat model of heart failure. Chin Med J (Engl) 2007, 120:2250-2255.
51. Candelore M.R., Deng L., Tota L., Guan X.M., Amend A., Liu Y., et al. Potent and selective human beta(3)-adrenergic receptor antagonists. J Pharmacol Exp Ther 1999, 290:649-655.
52. Niclauss N., Michel-Reher M.B., Alewijnse A.E., Michel M.C. Comparison of three radioligands for the labelling of human beta-adrenoceptor subtypes. Naunyn Schmiedebergs Arch Pharmacol 2006, 374:99-105.
53. Brahmadevara N., Shaw A.M., MacDonald A. Alpha1-adrenoceptor antagonist properties of CGP 12177A and other beta-adrenoceptor ligands: evidence against beta(3)- or atypical beta-adrenoceptors in rat aorta. Br J Pharmacol 2004, 142:781-787.
54. Briones A.M., Daly C.J., Jimenez-Altayo F., Martinez-Revelles S., Gonzalez J.M., McGrath J.C., et al. Direct demonstration of beta1- and evidence against beta2- and beta3-adrenoceptors, in smooth muscle cells of rat small mesenteric arteries. Br J Pharmacol 2005, 146:679-691.
55. Leblais V., Pourageaud F., Ivorra M.D., Marthan R., Muller B. Comparison of the alpha-adrenoceptor-mediated effects of beta3-adrenoceptor ligands in rat pulmonary artery. Naunyn Schmiedebergs Arch Pharmacol 2005, 371:535-539.
56. Horinouchi T., Koike K. Agonistic activity of SR59230A at atypical beta-adrenoceptors in guinea pig gastric fundus and duodenum. Eur J Pharmacol 2001, 416:165-168.
57. Hutchinson D.S., Sato M., Evans B.A., Christopoulos A., Summers R.J. Evidence for pleiotropic signaling at the mouse beta3-adrenoceptor revealed by SR59230A [3-(2-Ethylphenoxy)-1-[(1, S)-1, 2, 3, 4-tetrahydronapth-1-ylamino]-2S-2-propa nol oxalate]. J Pharmacol Exp Ther 2005, 312:1064-1074.
58. Belge C., Sekkali B., Tavernier G., Pouleur A.C., Bertrand L., Vanoverschelde J.L., et al. Cardiomyocyte-specific overexpression of Beta3-adrenoceptors attenuates the hypertrophic response to catecholamines in vivo. Circulation 2007, 116:II_148.
59. Morimoto A., Hasegawa H., Cheng H.J., Cheng C.P. Endogenous beta3-adrenoreceptor activation contributes to left ventricular and cardiomyocyte dysfunction in heart failure. Am J Physiol Heart Circ Physiol 2004, 286:H2425-H2433.
60. Brixius K., Bloch W., Pott C., Napp A., Krahwinkel A., Ziskoven C., et al. Mechanisms of beta 3-adrenoceptor-induced eNOS activation in right atrial and left ventricular human myocardium. Br J Pharmacol 2004, 143:1014-1022.
61. Brixius K., Bloch W., Ziskoven C., Bolck B., Napp A., Pott C., et al. Beta3-adrenergic eNOS stimulation in left ventricular murine myocardium. Can J Physiol Pharmacol 2006, 84:1051-1060.
62. Massion P.B., Dessy C., Desjardins F., Pelat M., Havaux X., Belge C., et al. Cardiomyocyte-restricted overexpression of endothelial nitric oxide synthase (NOS3) attenuates beta-adrenergic stimulation and reinforces vagal inhibition of cardiac contraction. Circulation 2004, 110:2666-2672.
63. Moens A.L., Kass D.A. Tetrahydrobiopterin and cardiovascular disease. Arterioscler Thromb Vasc Biol 2006, 26:2439-2444.
64. Fleming I., Busse R. Molecular mechanisms involved in the regulation of the endothelial nitric oxide synthase. Am J Physiol Regul Integr Comp Physiol 2003, 284:R1-R12.
65. Bauer P.M., Fulton D., Boo C., Sorescu G.P., Kemp B.E., Jo H., et al. Compensatory phosphorylation and protein-protein interactions revealed by loss of function and gain of function mutants of multiple serine phosphorylation sites in endothelial nitric-oxide synthase. J Biol Chem 2003, 273(17):14841-14849.
66. Kou R., Greif D., Michel T. Dephosphorylation of endothelial nitric-oxide synthase by vascular endothelial growth factor. Implications for the vascular responses to cyclosporin A. J Biol Chem 2002, 277:29669-29673.
67. van der Heyden M.A., Wijnhoven T.J., Opthof T. Molecular aspects of adrenergic modulation of cardiac L-type Ca2+ channels. Cardiovasc Res 2005, 65(1):28-39.
68. Xiong L., Kleerekoper Q.K., He R., Putkey J.A., Hamilton S.L. Sites on calmodulin that interact with the C-terminal tail of Cav1.2 channel. J Biol Chem 2005, 280(8):7070-7079.
69. Zhang Z.S., Cheng H.J., Onishi K., Ohte N., Wannenburg T., Cheng C.P. Enhanced inhibition of L-type Ca2+ current by beta3-adrenergic stimulation in failing rat heart. J Pharmacol Exp Ther 2005, 315(3):1203-1211.
70. Xu K.Y., Huso D.L., Dawson T.M., Bredt D.S., Becker L.C. Nitric oxide synthase in cardiac sarcoplasmic reticulum. Proc Natl Acad Sci USA 1999, 96:657-662.
71. Angelone T., Quintieri A.M., Brar B.K., Limchaiyawat P.T., Tota B., Mahata S.K., et al. The antihypertensive chromogranin a peptide catestatin acts as a novel endocrine/paracrine modulator of cardiac inotropism and lusitropism. Endocrinology 2008, 149(10):4780-4793.
72. Wang H., Kohr M.J., Traynham C.J., Wheeler D.G., Janssen P.M., Ziolo M.T. Neuronal nitric oxide synthase signaling within cardiac myocytes targets phospholamban. Am J Physiol Cell Physiol 2008, 294(6):1566-1575.
73. Zhang Y.H., Zhang M.H., Sears C.E., Emanuel K., Redwood C., El-Armouche A., et al. Reduced phospholamban phosphorylation is associated with impaired relaxation in left ventricular myocytes from neuronal NO synthase-deficient mice. Circ Res 2008, 102(2):242-249.
74. Bendall J.K., Damy T., Ratajczak P., Loyer X., Monceau V., Marty I., et al. Role of myocardial neuronal nitric oxide synthase-derived nitric oxide in beta-adrenergic hyporesponsiveness after myocardial infarction-induced heart failure in rat. Circulation 2004, 110:2368-2375.
75. Dawson D., Lygate C.A., Zhang M.H., Hulbert K., Neubauer S., Casadei B. nNOS gene deletion exacerbates pathological left ventricular remodeling and functional deterioration after myocardial infarction. Circulation 2005, 112:3729-3737.
76. Saraiva R.M., Minhas K.M., Raju S.V., Barouch L.A., Pitz E., Schuleri K.H., et al. Deficiency of neuronal nitric oxide synthase increases mortality and cardiac remodeling after myocardial infarction: role of nitroso-redox equilibrium. Circulation 2005, 112:3415-3422.
77. Birenbaum A., Tesse A., Loyer X., Michelet P., Andriantsitohaina R., Heymes C., et al. Involvement of beta 3-adrenoceptor in altered beta-adrenergic response in senescent heart: role of nitric oxide synthase 1-derived nitric oxide. Anesthesiology 2008, 109:1045-1053.
78. Dincer U.D., Bidasee K.R., Guner S., Tay A., Ozcelikay A.T., Altan V.M. The effect of diabetes on expression of beta1-, beta2-, and beta3-adrenoreceptors in rat hearts. Diabetes 2001, 50:455-461.
79. Idigo W., Zhang M.H., Zhang Y.H., Casadei B. The negative inotropic effect of [beta]3-adrenergic receptor stimulation in nNOS-/- mice is restored by oxypurinol. Heart 2006, 92:e1 008.
80. Khan S.A., Lee K., Minhas K.M., Gonzalez D.R., Raju S.V., Tejani A.D., et al. Neuronal nitric oxide synthase negatively regulates xanthine oxidoreductase inhibition of cardiac excitation-contraction coupling. Proc Natl Acad Sci USA 2004, 101:15944-15948.
81. Shen Y.T., Cervoni P., Claus T., Vatner S.F. Differences in beta 3-adrenergic receptor cardiovascular regulation in conscious primates, rats and dogs. J Pharmacol Exp Ther 1996, 278:1435-1443.
82. Shen Y.T., Zhang H., Vatner S.F. Peripheral vascular effects of beta-3 adrenergic receptor stimulation in conscious dogs. J Pharmacol Exp Ther 1994, 268:466-473.
83. Lacroix J.S., Kurt A.M., Auberson S., Bretton C. Beta-adrenergic mechanisms in the nasal mucosa vascular bed. Eur Arch Otorhinolaryngol 1995, 252:298-303.
84. Rohrer D.K., Chruscinski A., Schauble E.H., Bernstein D., Kobilka B.K. Cardiovascular and metabolic alterations in mice lacking both beta1- and beta2-adrenergic receptors. J Biol Chem 1999, 274:16701-16708.
85. Ignarro L.J., Byrns R.E., Trinh K., Sisodia M., Buga G.M. Nebivolol: a selective beta(1)-adrenergic receptor antagonist that relaxes vascular smooth muscle by nitric oxide- and cyclic GMP-dependent mechanisms. Nitric Oxide 2002, 7(2):75-82.
86. Barbe P., Millet L., Galitzky J., Lafontan M., Berlan M. In situ assessment of the role of the beta 1-, beta 2-, and beta 3-adrenoceptors in the control of liplysis and nutrive blood flow in human subcutaneous adipose tissue. Br J Pharmacol 1996, 117:907-913.
87. Larsen T.M., Toubro S., van Baak M.A., Gottesdiener K.M., Larson P., Saris W.H., et al. Effect of a 28-d treatment with L-796568, a novel beta(3)-adrenergic receptor agonist, on energy expenditure and body composition in obese men. Am J Clin Nutr 2002, 76:780-788.
88. Tagaya E., Tamaoki J., Takemura H., Isono K., Nagai A. Atypical adrenoceptor-mediated relaxation of canine pulmonary artery through a cyclic adenosine monophosphate-dependent pathway. Lung 1999, 177:321-332.
89. Tamaoki J., Tagaya E., Isono K., Nagai A. Atypical adrenoceptor-mediated relaxation of canine pulmonary artery through a cAMP-dependent pathway. Biochem Biophys Res Commun 1998, 248:722-727.
90. Oriowo M.A. Atypical beta-adrenoceptors in the rat isolated common carotid artery. Br J Pharmacol 1994, 113:699-702.
91. Trochu J.N., Leblais V., Rautureau Y., Beverelli F., Le Marec H., Berdeaux A., et al. Beta 3-adrenoceptor stimulation induces vasorelaxation mediated essentially by endothelium-derived nitric oxide in rat thoracic aorta. Br J Pharmacol 1999, 128:69-76.
92. Rautureau Y., Toumaniantz G., Serpillon S., Jourdon P., Trochu J.N., Gauthier C. Beta 3-adrenoceptor in rat aorta: molecular and biochemical characterization and signalling pathway. Br J Pharmacol 2002, 137:153-161.
93. Kou R., Michel T. Epinephrine regulation of the endothelial nitric-oxide synthase: roles of RAC1 and beta3-adrenergic receptors in endothelial NO signaling. J Biol Chem 2007, 282:32719-32729.
94. Feldman R.D. Beta-adrenergic receptor alterations in hypertension-physiological and molecular correlates. Can J Physiol Pharmacol 1987, 65:1666-1672.
95. Werstiuk E.S., Lee R.M. Vascular beta-adrenoceptor function in hypertension and in ageing. Can J Physiol Pharmacol 2000, 78:433-452.
96. Donckier J.E., Massart P.E., Van Mechelen H., Heyndrickx G.R., Gauthier C., Balligand J.L. Cardiovascular effects of beta 3-adrenoceptor stimulation in perinephritic hypertension. Eur J Clin Invest 2001, 31:681-689.
97. Mallem M.Y., Toumaniantz G., Serpillon S., Gautier F., Gogny M., Desfontis J.C., et al. Impairment of the low-affinity state beta1-adrenoceptor-induced relaxation in spontaneously hypertensive rats. Br J Pharmacol 2004, 143:599-605.
98. Tavernier G., Toumaniantz G., Erfanian M., Heymann M.F., Laurent K., Langin D., et al. beta3-Adrenergic stimulation produces a decrease of cardiac contractility ex vivo in mice overexpressing the human beta3-adrenergic receptor. Cardiovasc Res 2003, 59:288-296.
99. Barbier J., Mouas C., Rannou-Bekono F., Carre F. Existence of beta(3)-adrenoceptors in rat heart: functional implications. Clin Exp Pharmacol Physiol 2007, 34:796-798.
100. Cheng H.J., Zhang Z.S., Onishi K., Ukai T., Sane D.C., Cheng C.P. Upregulation of functional beta(3)-adrenergic receptor in the failing canine myocardium. Circ Res 2001, 89:599-606.
101. Kitamura T., Onishi K., Dohi K., Okinaka T., Isaka N., Nakano T. The negative inotropic effect of beta3-adrenoceptor stimulation in the beating guinea pig heart. J Cardiovasc Pharmacol 2000, 35:786-790.
102. Skeberdis V.A., Gendviliene V., Zablockaite D., Treinys R., Macianskiene R., Bogdelis A., et al. beta3-adrenergic receptor activation increases human atrial tissue contractility and stimulates the L-type Ca2+ current. J Clin Invest 2008, 118:3219-3227.
103. Takayama S., Furukawa Y., Ren L.M., Inoue Y., Sawaki S., Chiba S. Positive chronotropic and inotropic responses to BRL 37344, a beta 3-adrenoceptor agonist in isolated, blood-perfused dog atria. Eur J Pharmacol 1993, 231:315-321.
104. Imbrogno S., Angelone T., Adamo C., Pulera E., Tota B., Cerra M.C. Beta3-adrenoceptor in the eel (Anguilla anguilla) heart: negative inotropy and NO-cGMP-dependent mechanism. J Exp Biol 2006, 209:4966-4973.
105. Au A.L., Kwan Y.W. Modulation of L-type Ca2+ channels by beta3-adrenoceptor activation and the involvement of nitric oxide. J Card Surg 2002, 17:465-469.
106. Moniotte S., Balligand J.L. Potential use of beta(3)-adrenoceptor antagonists in heart failure therapy. Cardiovasc Drug Rev 2002, 20:19-26.
107. Rozec B., Noireaud J., Trochu J.N., Gauthier C. Place of beta 3-adrenoceptors among other beta-adrenoceptor subtypes in the regulation of the cardiovascular system. Arch Mal Coeur Vaiss 2003, 96:905-913.
108. Napp A., Brixius K., Pott C., Ziskoven C., Boelck B., Mehlhorn U., et al. Effects of the beta3-adrenergic agonist BRL 37344 on endothelial nitric oxide synthase phosphorylation and force of contraction in human failing myocardium. J Card Fail 2009, 15:57-67.
109. Ziskoven C., Grafweg S., Bolck B., Wiesner R.J., Jimenez M., Giacobino J.P., et al. Increased Ca2+ sensitivity and protein expression of SERCA 2a in situations of chronic beta3-adrenoceptor deficiency. Pflugers Arch 2007, 453:443-453.
110. Wagner K.D., Geil D., Schimke I., Stauss H.M., Lammerich A., Theres H., et al. Decreased susceptibility of contractile function to hypoxia/reoxygenation in chronic infarcted rat hearts. J Mol Cell Cardiol 1998, 30:2341-2353.
111. Cross H.R., Steenbergen C., Lefkowitz R.J., Koch W.J., Murphy E. Overexpression of the cardiac beta(2)-adrenergic receptor and expression of a beta-adrenergic receptor kinase-1 (betaARK1) inhibitor both increase myocardial contractility but have differential effects on susceptibility to ischemic injury. Circ Res 1999, 85:1077-1084.
112. Engelhardt S., Hein L., Keller U., Klambt K., Lohse M.J. Inhibition of Na(+)-H(+) exchange prevents hypertrophy, fibrosis, and heart failure in beta(1)-adrenergic receptor transgenic mice. Circ Res 2002, 90:814-819.
113. Rozec B., Erfanian M., Laurent K., Trochu J.N., Gauthier C. Nebivolol, a vasodilating selective beta(1)-blocker, is a beta(3)-adrenoceptor agonist in the nonfailing transplanted human heart. J Am Coll Cardiol 2009, 53(17):1532-1538.
114. Moens AL, Leyton-Mange JS, Niu X, Yang R, Cingolani O, Arkenbout EK, et al. Adverse ventricular remodeling and exacerbated NOS uncoupling from pressure-overload in mice lacking the beta3-adrenoreceptor. J Mol Cell Cardiol 2009;47(5):576-85.